Merck & Co. opens the week with earnings focus, shares in New York

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 09:20.

Merck & Co. (US58933Y1055) opens the week with an earnings calendar anchor on NYSE. MarketBeat lists the next MRK earnings date and the last New York close at 128.35 dollars according to MarketBeat.

What the calendar shows

MarketBeat shows MRK at 128.35 dollars at the 06/26/2026 close, with extended trading quoted at 128.22 dollars. The same page tracks earnings dates, estimates, and call transcripts for Merck & Co. MarketBeat earnings page

Sunday gives the stock a clean schedule angle. The next checkpoint on the page is the company’s earnings date, which keeps attention on the quarterly calendar rather than on intraday noise.

Consensus and peer context

For a broader view, Merck & Co. sits in the same large-cap U.S. pharmaceutical group as Pfizer and Bristol Myers Squibb. That peer frame matters for retail investors comparing earnings cadence, patent exposure, and vaccine-related revenue lines.

In the U.S. large-cap health-care sector, the NYSE listing keeps MRK visible for global investors who track New York closes, extended trading, and the next earnings print on one page.

Key products behind the stock

Merck & Co. is best known for Keytruda, its cancer therapy, and Gardasil, the vaccine franchise that still shapes the company’s revenue profile. Those two products remain central to how investors read the stock.

The listing in New York

The Merck & Co. shares (US58933Y1055) trade on 2026-06-28, 09:20 UTC on NYSE at 128.35 dollars.